Table 1.
Clinicopathological and molecular data of colon adenomas and carcinomas
| TA (n = 8) | SSA (n = 19) | MSS (n = 12) | MSI (n = 13) | P-value 3 | |
|---|---|---|---|---|---|
|
Age |
65.4 ± 4.4 |
60.6 ± 9.8 |
62.2 ± 8.2 |
70.8 ± 11.3 |
0.019
(a)
|
|
Gender (M/F) |
4/4 |
13/6 |
6/6 |
6/7 |
0.57 |
|
Duke’s stage |
NA |
NA |
7/5 |
11/2 |
0.20 |
|
(A or B/C) | |||||
|
Grade
1
|
NA |
NA |
12/0 |
9/4 |
0.096 |
|
(W-M/P) | |||||
|
KRAS
Mutations |
4/8 |
0/19 |
4/12 |
0/13 |
0.0011 |
|
(mut/total) | |||||
|
BRAF
Mutations |
0/8 |
19/19 |
4/12 |
9/13 |
2.2×10
-6
|
|
(mut/total) | |||||
|
hMLH1
Methylation (+/total ) |
0/8 |
0/19 |
0/12 |
5/13 |
8.6×10
-4
|
|
Hypermethylation
2
|
1.8 ± 1.4% |
1.2 ± 0.6% |
1.2 ± 0.6% |
1.9 ± 1.2% |
0.15(a) |
| Hypomethylation 2 | 0.6 ± 0.4% | 0.3 ± 0.2% | 1.0 ± 0.5% | 1.0 ± 0.6% | 5.8×10 -4 (a) |
1Tumor grade. Well (W), moderately (M) or poorly (P) differentiated.
2Hypermethylation and hypomethylation indicate the percentage of MS-AFLP array probes with values surpassing the hypermethylation and hypomethylation thresholds, respectively.
3For categorical data, p-values were calculated by χ2 test when comparing four groups, or by Fisher’s exact test when comparing two groups. For continuous data, we applied one-way ANOVA followed by Tukey’s HSD multi-hypothesis testing correction. The most Statistically significant p-value after correction corresponded always to the SSA vs MSI comparison(a). In hypomethylation, a significant difference between SSA and MSS was also found (P = 0.0014). P-values below 0.05 are in bold type.
NA: Not applicable.